Benta 480 SL

Primær information

  • Handelsnavn:
  • Benta 480 SL Vandopløseligt koncentrat
  • Lægemiddelform:
  • Vandopløseligt koncentrat
  • Sammensætning:
  • 480 g/l bentazon
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Benta 480 SL Vandopløseligt koncentrat
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Markedsført
  • Autorisationsnummer:
  • 653-8
  • Sidste ændring:
  • 07-02-2018

Indlægsseddel

Der er ingen sikkerhedsadvarsler relateret til dette produkt.

23-3-2018

GLIZIGEN GEL INTIMATE (Glycerin) Gel [Catalysis, SL]

GLIZIGEN GEL INTIMATE (Glycerin) Gel [Catalysis, SL]

Updated Date: Mar 23, 2018 EST

US - DailyMed

19-3-2018

GLIZIGEN SINGLE DOSE INTIMATE GEL (Glycerin) Gel [Catalysis, SL]

GLIZIGEN SINGLE DOSE INTIMATE GEL (Glycerin) Gel [Catalysis, SL]

Updated Date: Mar 19, 2018 EST

US - DailyMed

5-3-2018

ALOPEL FOAM (Glycerin) Aerosol, Foam [Catalysis, SL]

ALOPEL FOAM (Glycerin) Aerosol, Foam [Catalysis, SL]

Updated Date: Mar 5, 2018 EST

US - DailyMed

5-3-2018

FOLREX CREAM (Menthol) Cream [Catalysis, SL]

FOLREX CREAM (Menthol) Cream [Catalysis, SL]

Updated Date: Mar 5, 2018 EST

US - DailyMed

16-1-2018

GRANEX FOAM ACNE TREATMENT (Salicylic Acid) Aerosol, Foam [Catalysis, SL]

GRANEX FOAM ACNE TREATMENT (Salicylic Acid) Aerosol, Foam [Catalysis, SL]

Updated Date: Jan 16, 2018 EST

US - DailyMed

12-1-2018

GLYZIGEN SINGLE DOSE INTIMATE GEL (Glycerin) Gel [Catalysis, SL]

GLYZIGEN SINGLE DOSE INTIMATE GEL (Glycerin) Gel [Catalysis, SL]

Updated Date: Jan 12, 2018 EST

US - DailyMed

22-11-2017

EU/3/16/1806 (Abeona Therapeutics Europe SL)

EU/3/16/1806 (Abeona Therapeutics Europe SL)

EU/3/16/1806 (Active substance: Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene) - Transfer of orphan designation - Commission Decision (2017)7864 of Wed, 22 Nov 2017 European Medicines Agency (EMA) procedure number: EMA/OD/195/16/T/01

Europe -DG Health and Food Safety

14-11-2017

EU/3/17/1835 (Abeona Therapeutics Europe SL)

EU/3/17/1835 (Abeona Therapeutics Europe SL)

EU/3/17/1835 (Active substance: Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the COL7A1 gene) - Transfer of orphan designation - Commission Decision (2017)7626 of Tue, 14 Nov 2017 European Medicines Agency (EMA) procedure number: EMA/OD/283/16/T/01

Europe -DG Health and Food Safety

14-11-2017

EU/3/16/1825 (Abeona Therapeutics Europe SL)

EU/3/16/1825 (Abeona Therapeutics Europe SL)

EU/3/16/1825 (Active substance: Recombinant adeno-associated viral vector serotype 9 containing the human N-alpha-acetylglucosaminidase gene) - Transfer of orphan designation - Commission Decision (2017)7629 of Tue, 14 Nov 2017 European Medicines Agency (EMA) procedure number: EMA/OD/226/16/T/01

Europe -DG Health and Food Safety

14-11-2017

EU/3/16/1761 (Abeona Therapeutics Europe SL)

EU/3/16/1761 (Abeona Therapeutics Europe SL)

EU/3/16/1761 (Active substance: Self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene) - Transfer of orphan designation - Commission Decision (2017)7627 of Tue, 14 Nov 2017 European Medicines Agency (EMA) procedure number: EMA/OD/164/16/T/01

Europe -DG Health and Food Safety

10-10-2017

HYOSCYAMINE SULFATE SL (Hyoscyamine Sulfate) Tablet [Acella Pharmaceuticals, LLC]

HYOSCYAMINE SULFATE SL (Hyoscyamine Sulfate) Tablet [Acella Pharmaceuticals, LLC]

Updated Date: Oct 10, 2017 EST

US - DailyMed

25-8-2017

EU/3/17/1911 (Ability Pharmaceuticals SL)

EU/3/17/1911 (Ability Pharmaceuticals SL)

EU/3/17/1911 (Active substance: Sodium 2-hydroxylinoleate) - Orphan designation - Commission Decision (2017)5920 of Fri, 25 Aug 2017 European Medicines Agency (EMA) procedure number: EMA/OD/078/17

Europe -DG Health and Food Safety

31-7-2017

EFFECTIVE HAIR STRENGTHEN (Glycerin) Solution [NUGGELA SULE SL]

EFFECTIVE HAIR STRENGTHEN (Glycerin) Solution [NUGGELA SULE SL]

Updated Date: Jul 31, 2017 EST

US - DailyMed

31-7-2017

HAIR TREATMENT PREMIUM (Glycerin) Shampoo [NUGGELA SULE SL]

HAIR TREATMENT PREMIUM (Glycerin) Shampoo [NUGGELA SULE SL]

Updated Date: Jul 31, 2017 EST

US - DailyMed

28-7-2017

HAIR REGENERATOR (Glycerin) Solution [NUGGELA SULE SL]

HAIR REGENERATOR (Glycerin) Solution [NUGGELA SULE SL]

Updated Date: Jul 28, 2017 EST

US - DailyMed

29-6-2017

CICATRIX SKIN PROTECTANT (Glycerin) Cream [Catalysis, SL]

CICATRIX SKIN PROTECTANT (Glycerin) Cream [Catalysis, SL]

Updated Date: Jun 29, 2017 EST

US - DailyMed

29-6-2017

GLIZIGEN SKIN PROTECTANT (Glycerin) Spray [Catalysis, SL]

GLIZIGEN SKIN PROTECTANT (Glycerin) Spray [Catalysis, SL]

Updated Date: Jun 29, 2017 EST

US - DailyMed

20-6-2017

Xagrid (Shire Pharmaceutical Contracts Ltd)

Xagrid (Shire Pharmaceutical Contracts Ltd)

Xagrid (Active substance: anagrelide) - PSUSA - Modification - Commission Decision (2017)4319 of Tue, 20 Jun 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/480/PSUSA/208/201609

Europe -DG Health and Food Safety